Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Down 2.6% – Should You Sell?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX)’s stock price fell 2.6% during mid-day trading on Monday . The stock traded as low as $0.62 and last traded at $0.64. 196,853 shares changed hands during trading, a decline of 35% from the average session volume of 304,344 shares. The stock had previously closed at $0.6573.

Wall Street Analysts Forecast Growth

SLRX has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Salarius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Salarius Pharmaceuticals Trading Down 2.6%

The company has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $5.89. The stock has a market cap of $3.75 million, a P/E ratio of -0.02 and a beta of 0.40.

Salarius Pharmaceuticals (NASDAQ:SLRX) last announced its earnings results on Friday, November 14th. The company reported ($1.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($33.60) by $31.79.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.